


MOMENTUM IN OUR DYNAMIC PIPELINE BASED ON EMERGING DATA

WAVE 1¹

WAVE 2²

TARGET APPROVAL	CLINICAL-STAGE NMEs					FY25/26	FY27 AND BEYOND				
	FY20	FY21	FY22	FY23	FY24						
 ONCOLOGY		 mobocertinib 2L NSCLC with EGFR exon 20 insertion mutation ³	 pevoneditat HR-MDS	 mobocertinib 1L NSCLC with EGFR exon 20 insertion mutation	 pevoneditat Unfit AML	 TAK-981 Multiple cancers	 TAK-605 Multiple cancers	 TAK-252 Solid tumors	 TAK-102 Multiple cancers		
 RARE GENETIC & HEMATOLOGY		 maribavir R/R CMV infect. in transplant	 maribavir 1L CMV infect. in HSCT	 TAK-611 MLD (IT)	 TAK-755 cTTP	 TAK-755 iTTP, SCD	 mezagitimab MG, ITP	 TAK-607 Complications of prematurity			
 NEUROSCIENCE			 soticlestat DEE	 Orexin2R-ag (TAK-925/994) Narcolepsy T1		 Orexin2R-ag Sleep Disorders		 TAK-341 Parkinson's Disease	 TAK-071 Parkinson's Disease		
 GASTRO-ENTEROLOGY		 TAK-721⁴ EoE				 TAK-062 Celiac Disease	 TAK-101 Celiac Disease		 sibofimloc Crohn's Disease (post-op and ileitis)	 TAK-671 Acute Pancreatitis	 TAK-039 Hepatic encephalopathy
 VACCINES			 TAK-003 Dengue Vaccine			 TAK-426 Zika Vaccine		 TAK-214 Norovirus Vaccine			
 PDT		 CoVig-19⁵ COVID-19 H-IG (Formerly TAK-888)				 Orphan potential in at least one indication	 Breakthrough and/or Fast Track Designations	 China Breakthrough and/or Japan SAKIGAKE Designation	 New addition to the pipeline		

1. Projected approval dates depend on data read-outs; some Wave 1 target approval dates assume accelerated approval

2. Certain Wave 2 programs may be accelerated into Wave 1 depending on future data read outs

3. Approval date assumes filing on Phase 2 data

4. Approval expected Q4 FY20 or early Q1 FY21

5. The National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) is sponsor of the study and manages execution of the trial. Timing of potential regulatory filing and approval is dependent on the study enrollment rate and successful completion of the clinical trial, and is subject to change.

Takeda's Fiscal Year ends March 31 of the following year; e.g. "FY20" refers to the twelve month period ending March 31, 2021.

All timelines are approximate estimates of February 4, 2021.

For glossary of disease abbreviations please refer to appendix.



MAXIMIZING THE VALUE OF OUR APPROVED AND REGIONAL THERAPIES

	PHASE 1 & 2	PHASE 3				FILED
ONCOLOGY	NINLARO® Proteasome inhibitor R/R MM triplet Tx (US, EU) NINLARO® Proteasome inhibitor R/R MM doublet Tx (US, EU)	ALUNBRIG® ALK inhibitor 2L ALK+NSCLC 2nd gen TKI (GL) NINLARO® Proteasome inhibitor Maint. ND MM no SCT (US, EU, CN)	NINLARO® Proteasome inhibitor Maint. ND MM post-SCT (US, EU) ALUNBRIG® ALK inhibitor 2L ALK+NSCLC H2H with alectinib (GL)	ICLUSIG® BCR-ABL inhibitor FL Ph+ ALL (US) Cabozantinib <i>Exelixis</i> VEGFR/RTK inhibitor 2L mNSCLC combo w/atezolizumab (JP)	Cabozantinib <i>Exelixis</i> VEGFR/RTK inhibitor mCRPC combo w/atezolizumab (JP)	NINLARO® Proteasome inhibitor Maint. ND MM no SCT (JP) Cabozantinib <i>Exelixis</i> VEGFR/RTK inhibitor 2L HCC (JP)
RARE GENETIC & HEMATOLOGY	NATPARA® PTH replacement Hypothyroidism (JP)	TAKHZYRO® Anti-kallikrein mAb HAE pediatric (GL) TAKHZYRO® Anti-kallikrein mAb HAE (JP)	OBIZUR® <i>Ipsen</i> FVIII replacement CHAWI (US, EU) TAKHZYRO® Anti-kallikrein mAb BMA (GL)	VONVENDI® vWF replacement vWD Adult Prophylaxis (GL) VONVENDI® vWF replacement vWD Pediatric on-demand (GL)	ADYNOVATE® Pediatric HemA (EU)	TAKHZYRO® Anti-kallikrein mAb HAE prophylaxis (CN)
NEUROSCIENCE						
GASTRO-ENTEROLOGY	ENTYVIO® α4β7 mAb Pediatric UC/CD (GL)		ALOFISEL® mesenchymal stem cells Perianal Fistulas in CD (US, JP)	Vonoprazan PCAB Oral disintegrated tablet formulation (JP)	ENTYVIO® α4β7 mAb SubQ UC (US, JP)	Vonoprazan PCAB Reflex Esophagitis Maintenance (CN) Vonoprazan PCAB Duodenal ulcer (CN)
VACCINES	TAK-919 <i>Moderna</i> COVID-19 Vaccine (JP)	TAK-019 ¹ <i>Novavax</i> COVID-19 Vaccine (JP)	ENTYVIO® α4β7 mAb GvHD Prophylaxis (EU, JP)	ENTYVIO® α4β7 mAb SubQ CD (US, JP)	Vonoprazan PCAB H. Pylori (CN)	GATTEX® GLP-2R agonist Pediatric-SBS (JP) GATTEX® GLP-2R agonist Adult-SBS (JP)
PDT			CUVITRU® IgG 20% (human) subcutaneous PID (JP)	HYQVIA® <i>Halozyme</i> IgG 10% + Recombinant Human Hyaluronidase CIDP (US, EU)	HYQVIA® <i>Halozyme</i> IgG 10% + Recombinant Human Hyaluronidase Pediatric PID (US)	

● Orphan Drug Designation (in any region / indication for a given asset)

□ New regional addition to the pipeline

● Pivotal Ph-2 study

✗ Discontinued/deprioritized

► Clinical stage up since Q2 FY20

✓ Approved since Q2 FY20